Cardiac Hypertrophy: Causes, Symptoms, and Treatment

Cardiac hypertrophy is a thickening of the heart muscle that develops when the heart works harder than normal over a sustained period. It is not a disease on its own but a structural response to some underlying demand, whether that demand is healthy (like regular exercise or pregnancy) or harmful (like chronic high blood pressure or a damaged valve). The distinction between these two categories matters enormously: one form carries essentially no risk, while the other can progress to heart failure. Understanding what drives the thickening, what it feels like, and what can be done about it requires sorting through that divide.

Two Kinds of Thickened Heart Muscle

The heart is a muscle, and like any muscle it can grow in response to workload. When that growth happens because of normal demands, it is called physiological hypertrophy. Endurance athletes, for example, develop a mild-to-moderate increase in left ventricular wall thickness along with some chamber dilation, because their hearts pump larger volumes of blood during training.¹ Pregnancy produces a similar effect. In these cases, the heart’s internal architecture remains well organized and cardiac function stays normal or even improves.²

Pathological hypertrophy is a different story. It develops in response to prolonged abnormal stress, such as high blood pressure, heart valve disease, or a heart attack. The heart muscle thickens, but the growth is accompanied by scarring (fibrosis), loss of tiny blood vessels within the heart wall, increased inflammation, and cellular dysfunction.³ The heart also reactivates a set of genes normally active only in fetal development, which is a hallmark of maladaptive remodeling.² Over time, these changes stiff the heart, impair its ability to fill and pump, and raise the risk of heart failure.

What Causes Pathological Hypertrophy

The most common driver worldwide is high blood pressure. When the arteries resist blood flow, the left ventricle has to squeeze harder with every beat. Years of that extra pressure cause the wall to thicken concentrically, meaning the muscle grows inward and the chamber stays the same size or shrinks. A study of patients with resistant hypertension found that nighttime systolic blood pressure was one of the strongest predictors of this concentric thickening, along with age and obstructive sleep apnea.⁴ Sleep apnea alone roughly tripled the odds of concentric hypertrophy in that cohort, which explains why cardiologists increasingly screen for it in patients with unexplained heart thickening.

Valve disease is the other major hemodynamic cause. A narrowed aortic valve (aortic stenosis) forces the ventricle to generate higher pressure to push blood through the opening, producing concentric thickening much like hypertension does. A leaky mitral valve, on the other hand, allows blood to slosh backward, overloading the ventricle with extra volume. That volume overload produces eccentric hypertrophy, where the chamber dilates and the walls stretch out rather than thicken inward.⁵ Both patterns eventually compromise the heart’s pump function, but they do so through different structural routes.

Genetic Causes and Hypertrophic Cardiomyopathy

Not all cardiac hypertrophy stems from high blood pressure or damaged valves. Hypertrophic cardiomyopathy (HCM) is a genetic condition in which the heart muscle thickens without any obvious external trigger. Research has traced the cause to mutations in genes encoding sarcomere proteins, the molecular machinery that allows heart muscle cells to contract.⁶ These mutations are inherited in a dominant pattern, meaning a single copy of the faulty gene from one parent is enough to cause the disease.

HCM can appear at any age. In younger people, the thickening often becomes evident during adolescence when growth is rapid. But mutations in certain sarcomere proteins, including cardiac myosin-binding protein-C and troponin I, can cause hypertrophy that does not surface until later in life.⁷ Even before visible thickening develops on imaging, gene carriers can show subtle structural changes in the heart, which has sparked interest in screening family members of known patients.⁸

Under the microscope, HCM hearts display a characteristic pattern: the muscle cells are enlarged and disorganized, arranged in chaotic whorls rather than the tidy parallel fibers of a normal heart. Scarring and small-vessel disease are also common features.⁹ That disarray has practical consequences: it disrupts the electrical signals that coordinate heartbeat timing, which is why dangerous heart rhythms are a feared complication.

Symptoms and When People Notice Something Wrong

Early cardiac hypertrophy frequently produces no symptoms at all. Many people learn about it incidentally during an echocardiogram ordered for another reason. When symptoms do appear, they reflect the heart’s declining ability to fill efficiently and pump blood forward. The most common complaints are shortness of breath during exertion, chest discomfort, fatigue, lightheadedness or fainting, and palpitations. In obstructive HCM specifically, a thickened septum can partially block the outflow tract during contraction, creating an audible heart murmur and worsening symptoms with physical effort or dehydration.

The trouble is that these symptoms overlap with many other conditions, from deconditioning to anxiety to coronary artery disease. That vagueness means the diagnosis usually comes from imaging rather than from symptoms alone.

How It Is Diagnosed

Echocardiography, the standard heart ultrasound, remains the first-line tool for identifying hypertrophy. A wall thickness of 15 millimeters or more in any segment of the left ventricle typically meets the threshold for an HCM diagnosis when no other explanation is found. For hypertension-related hypertrophy, measuring left ventricular mass indexed to body size is the standard approach.

Cardiac MRI adds another layer of precision. It can measure wall thickness and total heart muscle mass more accurately than ultrasound and, uniquely, can detect areas of fibrosis within the muscle using a technique called late gadolinium enhancement.¹⁰ In a comparison study, echocardiography missed the diagnosis entirely in about 6% of HCM patients whose thickening was located in areas the ultrasound views could not capture well, particularly the anterolateral wall. MRI identified those cases and also detected extreme wall thickness that ultrasound had underestimated by about 20% in certain segments.¹¹

Blood-based biomarkers are also useful for tracking the severity and activity of hypertrophy. Markers of heart wall stretch, muscle cell death, fibrosis, and inflammation circulate at elevated levels in patients with HCM and can help gauge prognosis and treatment response.¹²

Conditions That Mimic Hypertrophic Cardiomyopathy

A thickened heart wall does not always mean HCM or hypertensive heart disease. Several infiltrative conditions can make the heart look hypertrophied on imaging when the actual problem is abnormal material depositing within the muscle. Cardiac amyloidosis, where misfolded proteins accumulate in heart tissue, and Fabry disease, a genetic disorder involving fat buildup in cells, are the two most important mimics. Getting the diagnosis right matters because each condition has a completely different treatment.

Distinguishing these conditions often requires combining clinical clues with advanced imaging. A study found that the presence of hypertension pointed toward hypertensive heart disease with good accuracy, while low blood pressure on standing and pericardial fluid collection suggested amyloidosis, and a papillary muscle abnormality helped identify classic HCM.¹³ Newer echocardiographic strain techniques that measure how different parts of the right ventricle contract have also shown strong ability to separate amyloidosis from Fabry disease and from HCM, with some parameters achieving very high discriminative accuracy.¹⁴

The Serious Complication Everyone Worries About

Sudden cardiac death is the most feared outcome of pathological hypertrophy, particularly in HCM. The disorganized muscle fibers and scarring create an electrical substrate prone to dangerous ventricular arrhythmias. At the cellular level, changes in ion channels, disrupted calcium handling, and heightened sensitivity of the contractile filaments to calcium can trigger abnormal electrical activity.¹⁵

Risk prediction models developed by European and American cardiology societies use factors like wall thickness, family history, unexplained fainting, and abnormal blood pressure response to exercise to estimate who might benefit from an implantable defibrillator. Adding cardiac MRI measurements of how the heart muscle contracts, specifically global longitudinal strain, has improved the accuracy of these predictions. In one study of about 2,000 HCM patients followed for over seven years, strain values independently predicted sudden death events even after accounting for the established risk factors and improved the predictive accuracy of both major risk models.¹⁶ Incorporating genetic information has also been shown to boost risk prediction beyond the standard clinical scoring.¹⁷

Drug Treatments

For hypertension-driven hypertrophy, the most effective strategy is lowering blood pressure. ACE inhibitors and angiotensin receptor blockers have been shown to reduce left ventricular mass and can even shrink individual heart muscle cells closer to normal size.¹⁸ Beta-blockers achieve similar reductions in heart mass. A comparison trial found that bisoprolol and enalapril lowered the left ventricular mass index to a comparable degree, by roughly 11% and 7% respectively, along with equivalent blood pressure control.¹⁹ This regression of hypertrophy is clinically meaningful: patients whose thickening shrank after two years of treatment had lower cardiovascular risk going forward.²⁰

For symptomatic HCM, beta-blockers and calcium channel blockers have long been the initial medications, aiming to slow the heart rate, ease outflow tract obstruction, and reduce symptoms. But these drugs do not address the underlying molecular problem in HCM.

Cardiac Myosin Inhibitors, a New Class of Drug

Mavacamten is the first drug designed specifically for the mechanism driving obstructive HCM. It works by reducing the excessive cross-bridging between actin and myosin, the two proteins that slide past each other to produce each heartbeat. By dialing down the force of contraction, it relieves the dynamic obstruction in the outflow tract.²¹ Clinical trials showed that it improved exercise capacity, reduced symptoms, and lowered pressure gradients across the outflow tract. A separate trial demonstrated that it could spare patients from needing surgical intervention altogether when surgery had previously seemed necessary.²¹

The drug requires careful dose titration because reducing contractility too far can cause heart failure symptoms. Dosing is guided by periodic echocardiograms and blood level monitoring to find the lowest effective dose for each individual.²² It is currently approved for symptomatic obstructive HCM in adults. For many patients, it has been transformative, offering symptom relief without the need for invasive procedures.

Surgery and Catheter-Based Procedures

When medications fail to control obstruction in HCM, two procedures can physically reduce the thickness of the septum. Septal myectomy is open-heart surgery in which a surgeon cuts away a strip of the thickened muscle. Alcohol septal ablation is a catheter-based alternative in which ethanol is injected into a small artery feeding the offending part of the septum, deliberately creating a tiny controlled heart attack that thins the muscle as it heals.

A meta-analysis comparing the two approaches found that myectomy produced a larger reduction in outflow tract pressure gradients and better symptom relief: about 95% of myectomy patients improved from severe to mild functional limitation, versus about 82% of ablation patients.²³ Ablation had fewer immediate complications but led to more pacemaker implantations and re-interventions. A large registry study following patients for a median of about six years found that the ten-year mortality rate was considerably higher in the ablation group compared to the myectomy group, even after adjusting for age, sex, and other health conditions.²⁴ The authors noted that unmeasured differences between patients chosen for each procedure might partly explain this gap, but the finding has shifted expert opinion further toward myectomy as the gold standard when surgery is feasible.

Exercise and Physical Activity

For decades, people diagnosed with HCM were told to avoid vigorous exercise and competitive sports entirely because of the fear of triggering sudden cardiac arrest. That blanket restriction is loosening. More recent data suggest that patients with HCM who participate in vigorous sports do not face a clearly higher rate of dangerous heart rhythms compared to those who stay less active.²⁵ The reported series of competitive athletes with HCM who continued competing remain small, but the outcomes have been reassuring so far.

Current guidelines from both American and European cardiology societies now recommend an individualized approach rather than a flat ban. The emphasis is on comprehensive evaluation, shared decision-making with a specialist, and honest discussion of the uncertainties involved.²⁶ This does not mean that every person with HCM gets the green light for any activity; high-risk features like very thick walls, prior fainting spells, or a family history of sudden death still prompt caution. But the days of reflexively sidelining every patient are fading.

Why the Pathological Form Goes Wrong at the Molecular Level

The reason pathological and physiological hypertrophy diverge so dramatically in outcomes comes down to which signaling programs they activate inside heart cells. Pathological stress turns on a specific molecular pathway involving calcineurin and a protein called NFAT. When calcineurin is active, it strips a phosphate group off NFAT, allowing NFAT to enter the nucleus and switch on genes associated with maladaptive growth and fibrosis.²⁷ This pathway stays active for weeks during pressure overload and ramps up even further after a heart attack.

Exercise-induced growth, by contrast, does not engage this pathway. In two separate models of exercise training in mice, calcineurin-NFAT signaling showed no meaningful activation despite clear increases in heart size. Growth hormone and IGF-1, the hormonal drivers of exercise-related hypertrophy, also failed to switch on calcineurin-NFAT, instead operating through a separate route involving the Akt pathway.²⁸ This molecular fork in the road explains why an athlete’s enlarged heart remains healthy while a hypertensive patient’s enlarged heart accumulates damage.

Recent work has also shown that syndecan-4, a protein on the surface of heart cells, can bind calcineurin directly and amplify NFAT activation during pressure overload. In mice engineered to produce extra syndecan-4 in heart cells, the calcineurin-NFAT response to pressure overload was exaggerated, leading to worse hypertrophy.²⁹ Findings like this are opening new therapeutic targets, because blocking specific molecules in the pathway could potentially halt pathological thickening without interfering with normal cardiac function.

Sex Differences in Cardiac Hypertrophy

Women and men respond differently to the same hypertrophic triggers. Pre-menopausal women tend to develop a less severe form of thickening for a given level of blood pressure or valve disease, a protection that appears to be driven largely by estrogen, which counteracts several pro-growth signaling pathways. After menopause, that protection diminishes substantially and is partially restored with estrogen replacement therapy.³⁰ Testosterone, by contrast, generally promotes hypertrophic growth. Mouse studies have identified a network centered on a metabolic regulator called PPARα that appears to mediate these sex differences; when PPARα was blocked, the gap between male and female hypertrophic responses disappeared.³¹

A complicating wrinkle: once hypertrophy is established, it carries a higher risk of progressing to heart failure in women than in men.³⁰ In HCM specifically, a cohort study from Vienna found that women presented at a significantly older age, had worse functional status (about 80% were in at least moderate functional limitation versus about half of men), and had more impaired diastolic function.³² Obstructive HCM was also more common in the women. These patterns suggest that women with HCM may be diagnosed later and arrive at clinical attention with more advanced disease, potentially because the initial protection from estrogen delays the onset of visible thickening.

Cardiac Hypertrophy in Infants of Diabetic Mothers

One unusual setting for cardiac hypertrophy involves newborns of mothers with poorly controlled diabetes during pregnancy. High maternal blood sugar triggers excess insulin production in the fetus, and insulin acts as a growth factor for the fetal heart, producing thickened walls and, occasionally, outflow tract obstruction. Most of these infants are asymptomatic and the hypertrophy resolves on its own within weeks to months as insulin levels normalize after birth. In rare cases, however, the obstruction is severe enough to compromise the baby’s circulation and require intensive support, including mechanical circulatory devices, until the thickening improves.³³ This transient form of hypertrophy is a completely different entity from genetic HCM and generally carries an excellent prognosis once the acute period passes.